Literature DB >> 8199003

An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii.

D J Ferguson1, J Huskinson-Mark, F G Araujo, J S Remington.   

Abstract

The morphological effects of drug treatment with atovaquone in the brains of mice chronically infected with Toxoplasma gondii was examined by light and electron microscopy. As early as 1 and 2 weeks of treatment there appeared to be fewer tissue cysts compared to untreated controls and this reduction was more significant after 4 weeks treatment. There also appeared to be a decrease in the number of inflammatory nodules and the severity of the meningitis. Ultrastructurally, the cysts of both treated and control animals were located within host cells. There was a marked increase in both the number of cysts with lysed bradyzoites and the number of degenerate bradyzoites after 4 weeks treatment. It is probable that the drug is more active against the metabolically active immature bradyzoites than the mature organisms. Drug treatment does not appear to result in rupture of tissue cysts or release of Toxoplasma antigens since there is a reduction rather than an increase in the inflammatory response. This drug may be useful in treating chronic toxoplasmosis since it appears to be active against the bradyzoites reducing the parasite burden (cyst number) without initiating a destructive inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8199003      PMCID: PMC2002108     

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  12 in total

1.  In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii.

Authors:  F G Araujo; J Huskinson-Mark; W E Gutteridge; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii.

Authors:  J Huskinson-Mark; F G Araujo; J S Remington
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

3.  Tissue cyst rupture in mice chronically infected with Toxoplasma gondii. An immunocytochemical and ultrastructural study.

Authors:  D J Ferguson; W M Hutchison; E Pettersen
Journal:  Parasitol Res       Date:  1989       Impact factor: 2.289

4.  An ultrastructural study of the early development and tissue cyst formation of Toxoplasma gondii in the brains of mice.

Authors:  D J Ferguson; W M Hutchison
Journal:  Parasitol Res       Date:  1987       Impact factor: 2.289

5.  Differences in virulence and development of encephalitis during chronic infection vary with the strain of Toxoplasma gondii.

Authors:  Y Suzuki; F K Conley; J S Remington
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

Review 6.  Toxoplasmic encephalitis in AIDS.

Authors:  B J Luft; J S Remington
Journal:  Clin Infect Dis       Date:  1992-08       Impact factor: 9.079

7.  566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients.

Authors:  A T Hudson; M Dickins; C D Ginger; W E Gutteridge; T Holdich; D B Hutchinson; M Pudney; A W Randall; V S Latter
Journal:  Drugs Exp Clin Res       Date:  1991

8.  The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.

Authors:  F G Araujo; T Lin; J S Remington
Journal:  J Infect Dis       Date:  1993-02       Impact factor: 5.226

9.  Cyst rupture as a pathogenic mechanism of toxoplasmic encephalitis.

Authors:  J K Frenkel; A Escajadillo
Journal:  Am J Trop Med Hyg       Date:  1987-05       Impact factor: 2.345

10.  Cerebral toxoplasmosis complicating the acquired immune deficiency syndrome: clinical and neuropathological findings in 27 patients.

Authors:  B A Navia; C K Petito; J W Gold; E S Cho; B D Jordan; R W Price
Journal:  Ann Neurol       Date:  1986-03       Impact factor: 10.422

View more
  13 in total

1.  Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.

Authors:  N Schöler; K Krause; O Kayser; R H Müller; K Borner; H Hahn; O Liesenfeld
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Reexamining Chronic Toxoplasma gondii Infection: Surprising Activity for a "Dormant" Parasite.

Authors:  Anthony P Sinai; Elizabeth A Watts; Animesh Dhara; Robert D Murphy; Matthew S Gentry; Abhijit Patwardhan
Journal:  Curr Clin Microbiol Rep       Date:  2016-10-04

Review 3.  Parasite powerhouse: A review of the Toxoplasma gondii mitochondrion.

Authors:  Madelaine M Usey; Diego Huet
Journal:  J Eukaryot Microbiol       Date:  2022-03-21       Impact factor: 3.880

4.  Temporal and spatial distribution of Toxoplasma gondii differentiation into Bradyzoites and tissue cyst formation in vivo.

Authors:  Manlio Di Cristina; Daniela Marocco; Roberto Galizi; Carla Proietti; Roberta Spaccapelo; Andrea Crisanti
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

Review 5.  Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

Review 6.  Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review.

Authors:  Mahbobeh Montazeri; Saeed Mehrzadi; Mehdi Sharif; Shahabeddin Sarvi; Shayesteh Shahdin; Ahmad Daryani
Journal:  Parasitol Res       Date:  2018-08-08       Impact factor: 2.289

7.  Biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from Toxoplasma gondii.

Authors:  Miryam Andrea Hortua Triana; My-Hang Huynh; Manuel F Garavito; Barbara A Fox; David J Bzik; Vern B Carruthers; Monika Löffler; Barbara H Zimmermann
Journal:  Mol Biochem Parasitol       Date:  2012-05-08       Impact factor: 1.759

8.  Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis.

Authors:  O Djurković-Djaković; T Nikolić; F Robert-Gangneux; B Bobić; A Nikolić
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

9.  Novel Approaches Reveal that Toxoplasma gondii Bradyzoites within Tissue Cysts Are Dynamic and Replicating Entities In Vivo.

Authors:  Elizabeth Watts; Yihua Zhao; Animesh Dhara; Becca Eller; Abhijit Patwardhan; Anthony P Sinai
Journal:  MBio       Date:  2015-09-08       Impact factor: 7.867

10.  Direct Effect of Two Naphthalene-Sulfonyl-Indole Compounds on Toxoplasma gondii Tachyzoite.

Authors:  Qasem Asgari; Hossein Keshavarz; Mostafa Rezaeian; Mohammad Hossein Motazedian; Saeedeh Shojaee; Mehdi Mohebali; Ramin Miri
Journal:  J Parasitol Res       Date:  2013-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.